Tasigna is a new prescription drug from Novartis that has been used for the treatment of leukemia. It was recently discovered that Tasigna can cause acute atherosclerosis (narrowing of the arteries that supply blood to the heart). Novartis has intentionally concealed this dangerous side effect and many individuals who were prescribed Tasigna have suffered serious injury and even death as a result.
Individuals who have suffered vascular damage as a result of their use of Tasigna may be entitled to financial compensation. A large number of Tasigna patients have already filed lawsuits against Novartis and the pending cases are about to be consolidated into a new class-action MDL. Our firm is currently accepting cases from anyone who took Tasigna and was subsequently diagnosed with atherosclerosis or suffered a related type of cardiovascular injury (i.e., heart attack, stroke, etc.)About Tasigna
Tasigna (nilotinib) is a prescription drug that is used to treat chronic myeloid leukemia (CML). CML is a type of cancer that originates in the bone marrow and enters the blood. CML accounts for about 15% of all adult leukemia cases.
Tasigna is a relatively new drug that was developed by Novartis and approved for use in the treatment of CML in 2007. Since its original release, Tasigna has become a very profitable drug for Novartis. Tasigna works by blocking certain proteins that cause leukemia cancer cells to grow. Tasigna comes in capsules or pills that are taken orally and range in dosage from 50 to 200 mg. Most patients take a twice-daily 300 mg dose of Tasigna.Tasigna Linked to Atherosclerosis and Arterial Disease
Not long after Tasigna was first released in 2007, adverse incident reports and other evidence began to appear indicating that the drug could be causing serious cardiovascular problems in some patients. In 2011, the results of several studies reported that the use of Tasigna was causing some patients to develop accelerated atherosclerosis.
Atherosclerosis is a condition in which the arteries delivering blood from the heart become hardened and narrow. Normally, atherosclerosis is something that can develop gradually over time as a person gets older. However, the use of Tasigna was causing certain patients to develop atherosclerosis within a few months. Atherosclerosis can be very dangerous as it can result in serious cardiac and vascular events such as heart attack, or peripheral arterial disease.
The evidence linking Tasigna to rapid atherosclerosis prompted Canadian health authorities to issue a public warning about the risks of Tasigna. In response, Novartis amended its Canadian prescribing information to include a warning that Tasigna can cause rapidly evolving vascular disease. Novartis deliberately chose not to add this warning to the prescribing information label for Tasigna in the U.S. In fact, the U.S. drug label for Tasigna still does not contain any information about the risk of atherosclerosis.Tasigna Lawsuits Against Novartis
A growing number of people who developed rapid atherosclerosis from using Tasigna and suffered serious injuries have filed lawsuits against Novartis. The lawsuits allege that Novartis knew as early as 2010 (and probably earlier) that Tasigna caused accelerated atherosclerosis and related conditions. Novartis knowingly and intentionally failed to warn about these risks in the U.S. in order to protect its financial interests.
One of the very first Tasigna lawsuits against Novartis was a wrongful death case filed back in 2016. That case was eventually resolved in a confidential settlement and this led to a number of new Tasigna cases being filed across the country. To date, about 125 individual plaintiffs have filed Tasigna lawsuits. Most of these cases have been filed in New Jersey state courts, but at least 20 were filed and are currently pending in the federal courts.
Hundreds more Tasigna lawsuits are anticipated moving forward and a request to create a new Tasigna class-action MDL was recently filed. The request is seeking to consolidate all future Tasigna cases in federal courts into an MDL in the Southern District of Illinois. If this request is granted it will facilitate the consolidated handling of all future Tasigna cases and most likely lead to a global settlement with Novartis.Our Firm is Seeking New Cases from Anyone Injured by Tasigna
Our firm is actively seeking new cases from anyone who was prescribed Tasigna for the treatment of CML and subsequently developed atherosclerosis or any of the following related conditions or events:
- Heart attack
- Peripheral artery disease
- Myocardial ischemia
If you took Tasigna and later developed any of these conditions (or other cardiovascular conditions or events) you may qualify to file a lawsuit against Novartis, participate in the litigation, and receive settlement proceeds to compensate for your injuries.See If You Qualify for a Tasigna Lawsuit
To see if you qualify to file a Tasigna lawsuit against Novartis, call our product liability lawyers today at 800-553-8082 or contact us online for a free case evaluation.